MAU2: A Potential Drug Target and Biomarker (G23383)

Target Name: MAU2

NCBI ID: G23383

MAU2

MAU2: A Potential Drug Target and Biomarker

Chromatin is the complex of DNA, RNA, and proteins that make up the chromosomes in the nucleus of a cell. Chromatin organization and dynamics are critical for the proper functioning of the cell, and the regulation of gene expression. One of the key components of chromatin organization is cohesion, the attraction of chromatin nucleosomes to each other. MAU2 (MAU2 chromatid cohesion factor homolog), a gene that encodes a protein involved in chromatin cohesion, has been identified as a potential drug target and biomarker for various diseases.

TheMAU2 gene was first identified in 2008 as a gene that was expressed in a variety of tissues, including brain, heart, liver, and muscle. The gene encodes a protein that is highly conserved across various species, and is known to be a key component of chromatin organization. Studies have shown that MAU2 is involved in the regulation of gene expression and is highly expressed in various tissues, including the brain.

In addition to its potential drug target and biomarker properties, MAU2 has also been linked to a number of diseases. For example, MAU2 has been shown to be highly expressed in the brains of individuals with Alzheimer's disease, a progressive neurodegenerative disorder that is characterized by the progressive loss of brain cells. Additionally, MAU2 has also been shown to be involved in the regulation of cancer cell growth and has been linked to the development of certain types of cancer.

The potential drug target properties of MAU2 are based on its involvement in the regulation of gene expression and its expression in various tissues. Drugs that target MAU2 have the potential to treat a variety of diseases, including those related to neurodegenerative disorders, cancer, and inflammation. For example, drugs that target MAU2 have been shown to be effective in treating neurodegenerative disorders, such as Alzheimer's disease, by increasing the levels of certain genes and decreasing the levels of others. Additionally, drugs that target MAU2 have also been shown to be effective in treating certain types of cancer by inhibiting the growth of cancer cells.

The potential biomarker properties of MAU2 are based on its involvement in the regulation of gene expression and its expression in various tissues. Tests have shown that individuals with certain genetic variations in the MAU2 gene are at increased risk of developing certain diseases, including Alzheimer's disease and certain types of cancer. Additionally, the expression of MAU2 has been shown to be associated with the development of certain diseases, such as neurodegenerative disorders.

In conclusion, MAU2 is a gene that has the potential to be a drug target and biomarker for a variety of diseases. Its involvement in the regulation of gene expression and its expression in various tissues make it an attractive target for drug development. Further research is needed to fully understand the role of MAU2 in disease and to develop effective treatments.

Protein Name: MAU2 Sister Chromatid Cohesion Factor

Functions: Plays an important role in the loading of the cohesin complex on to DNA. Forms a heterodimeric complex (also known as cohesin loading complex) with NIPBL/SCC2 which mediates the loading of the cohesin complex onto chromatin (PubMed:28167679, PubMed:22628566). Plays a role in sister chromatid cohesion and normal progression through prometaphase (PubMed:16802858, PubMed:16682347)

The "MAU2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAU2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets